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http://dxObjectives: Stent graft–related complications, including endoleaks and graft migration, are partly attributed to
insufficient graft attachment to the aortic wall. ONO-1301, a stable synthetic prostacyclin agonist, reportedly
reorganizes extracellular matrices, enhancing tissue healing. We hypothesized that ONO-1301–eluting stent
grafts may strengthen graft attachment to the aortic wall.
Methods: Polylactic acid polymer-conjugated ONO-1301, which releases ONO-1301 into adjacent tissues over
3 months (ONO(þ) group), or polylactic acid polymer only (ONO() group) was coated onto the stent graft
and placed in the descending thoracic aorta of canines weighing 16 to 20 kg under fluoroscopic guidance.
Examinations occurred at 1, 2, or 3 months postoperatively (n ¼ 6 for each time point and group).
Results: ONO-1301 aortic-wall concentrations were within the effective range even at 3 months. The maximal
load for tearing the graft from the aortic wall ex vivo was significantly greater in the ONO(þ) group than in the
ONO() group (117.1% 44.4%, 133.9% 23.2%, and 119.9% 13.5% at 1, 2, and 3months, respectively;
P ¼ .0007). Immunohistochemical examination revealed abundant a-smooth muscle actin–positive cells in the
neointima in both groups. The fibrotic area between the graft and the aortic wall was significantly larger
(P<.0001), and migrating cells into the graft fabric were significantly greater (P¼ .0003) in the ONO(þ) group
than in the ONO() group.
Conclusions: In canines, the ONO-1301–eluting stent graft enhanced tissue reorganization and improved the
attachment between the graft and the aortic wall. This new device may be useful in preventing inadequate graft
attachment to the aortic wall. (J Thorac Cardiovasc Surg 2014;148:2325-34)Supplemental material is available online.E
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SStent graft implantation via the endovascular approach has
been regarded as the standard treatment for atherosclerotic
aortic aneurysms in the last decade,1-3 although stent graft–
related complications such as stent migration, kinking, and
endoleaks have not been fully resolved. Malina and
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The Journal of Thoracic and Carimplanted stent graft and the native aortic wall was
histologically poor, contributing to stent graft–related
complications. It is theorized that adequate graft attachment
to the aorta would be accomplished by native cell migration
producing fibrotic tissues into the graft materials and
neointimal formation over the graft surface.
ONO-13015-8 is a chemically and biologically stable
synthetic prostacyclin agonist producing long-lasting
prostacyclin activity when administered in vivo. ONO-
1301 carries regenerative effects that enhance the native
biological healing process, such as reorganization of
fibrous tissue or vascular structures, by inducing vascular
endothelial growth factor (VEGF) or stromal cell-derived
factor (SDF)-1 expression in vascular smooth muscle cells
and fibroblasts.9-11 ONO-1301 can be conjugated with
polylactic acid (PLA) polymer to form ONO-1301
microspheres (ONO-1301MS) that release ONO-1301
into adjacent tissues for 3 to 4 months. We hypothesized
that the presence of ONO-1301MS in the stent graft may
strengthen the implanted stent graft attachment to the aortic
wall. Therefore, in the present study, we developed an
ONO-1301–eluting stent graft, which was inserted into
the thoracic descending aorta in a normal canine model,
to explore the feasibility, safety, and efficacy of this




PLA ¼ polylactic acid
SDF ¼ stromal cell-derived factor
SMA ¼ smooth muscle actin
VEGF ¼ vascular endothelial growth factor





The Osaka University Graduate School of Medicine ethics committee
approved the studies. All animals were treated in compliance with the
‘‘Guide for the Care and Use of Laboratory Animals’’ (National Institutes
of Health publication). Human cells were treated in compliance with the
Declaration of Helsinki.
Long-Release ONO-1301 Microsphere
ONO-1301 was conjugated with PLA polymers, rather than
polylactic and glycolic acid, as previously reported12 at ONO Pharma-
ceutical Company (Osaka, Japan). The drug-releasing capacity was
estimated in advance of this study, and these microspheres were
proven to have a longer release time (3-4 months) than polylactic and
glycolic acid–synthesized microspheres (Figure 1, A).8-11 ONO
Pharmaceutical Company provided the microspheres with or without
ONO-1301.
Preparation of ONO-1301–Eluting Stent Graft
A stainless-steel stent (Gianturco Z stent, 30 mm; Cook, Bloomington,
Ind) was sutured inside a Dacron woven graft (J Graft Woven-Graft,
WST series 14-18 mm; UBE Junken Medical, Tokyo, Japan) to create a
25-mm–long handmade stent graft (Figure 1, B). Subsequently, 5 mg/kg
of ONO-1301MS or PLA microspheres only was suspended in 10%
dissolved gelatin (HMG-BP; Nippi, Tokyo, Japan); this mixture was
applied to the outer surface of the stent graft and dried to create the stent
graft with (ONO(þ) group) or without (ONO() group) the ONO-1301
elution.
Fluoroscopy-Guided Endovascular Implantation of
the Stent Graft into a Canine Model
Mongrel dogs (16–20 kg; Oriental Yeast, Tokyo, Japan) underwent
general anesthesia by submucosal injection of 20 mg/kg ketamine
(Sankyo, Tokyo, Japan) and 2 mg/kg xylazine (Bayer Medical,
Tokyo, Japan), followed by intravenous infusion of 10 mg/kg/h propofol
(AstraZeneca, London, UK) and inhalation of 1.5% sevoflurane. First,
the thoracic descending aortic diameter was measured by computed
tomography angiography; then, on the basis of recommendations in
previous reports, we created a handmade stent graft that was 10% to
20% larger than the measured diameter.12,13
Subsequently, in the right lateral position, an 18F DrySeal sheath
(WL Gore & Associates, Inc, Flagstaff, Ariz) containing the stent graft
was introduced into the abdominal aorta via a retroperitoneal approach
under fluoroscopic guidance (Figure 1, C); then, the stent graft was
deployed into the thoracic descending aorta, followed by balloon
touch-up using a 20 3 40 mm MAXILD (Cordis; Johnson & Johnson,
Miami, Fla) (Figure 1, D). The animals were humanely killed at 1, 2,
or 3 months after the procedure under general anesthesia with an
overdose of intravenous sodium pentobarbital (18 mg/kg) to achieve
complete sedation followed by administration of potassium-based
solution intravenously to ensure that they were dead (n ¼ 6 for each
time point and group).2326 The Journal of Thoracic and Cardiovascular SurHandling of Specimens
The explanted aorta, including the stent grafts, was opened
longitudinally and photographed, and the stent materials were removed
from the graft for further assessment (Figure 1, E). Immediately after the
biomechanical test, the aortic wall tissue that dissociated from the graft
fabric was frozen to analyze the ONO-1301 concentration. Neointimal
tissues were separated from the graft and stored in RNAlater (Ambion,
Austin, Tex) at 20C.
ONO-1301 Concentrations in the Aortic Wall and
Blood Plasma
ONO-1301 concentrations in the aortic wall at 1, 2, and 3 months after
stent graft implantation were determined using liquid chromatography-
tandem mass spectrometry (n ¼ 4 at each time point). Blood samples
were obtained at 5 minutes, 3 hours, 1 week, 2 weeks, 1 month, 2 months,
and 3 months after stent graft implantation. ONO-1301 levels in the plasma
were measured by liquid chromatography-tandem mass spectrometry
(n ¼ 4 at each time point).14
Biomechanical Assessment
We performed biomechanical assessments using Tensilon RTC-1150A
(Orientec, Tokyo, Japan) on specimen sections measuring 5 3 10 mm.
The woven graft was pulled from the aortic wall by connecting it to the
metallic cylinder of the machine, which produced a constant tension
(50 mm/min), until the graft detached from the aorta. The associated
computer software recorded a load-deformation plot to measure the
maximum load (Newton [N]) required for graft displacement. Seven spe-
cimens were tested from each sample (n ¼ 6 at each time point) to obtain
the average value, after excluding the minimum and maximum values.
Histologic Assessment
The paraffin-embedded specimens were sliced at 0.5 mm and stained with
hematoxylin–eosin (HE) or Masson’s trichrome. The sections were labeled
with anti-CD31 antibody (Dako, Glostrup, Denmark) or anti-a-smooth mus-
cle actin (aSMA) antibody (Dako) and visualized by the labeled streptavidin
biotin staining method (Dako). The sections were labeled with primary anti-
bodies against CD31 (Dako), aSMA (Abcam, Cambridge, UK), fibroblast
specific antigen-1 (Abcam), or IP receptor (Abcam) and visualized by
fluorescence-conjugated secondary antibodies (Life Technologies, Grand
Island, NY), with counterstaining by Hoechst 33342 solution (Dojindo,
Kumamoto, Japan). The extent of the fibrotic area in the Masson’s tri-
chrome–stained sections was quantified using Biorevo BZ-9000 (Keyence,
Osaka, Japan) that calculated the ratio of the fibrotic area to the total tissue
area to provide an indication of the fibrous tissue accumulation in the gap be-
tween thegraft and the aorticwall. In each sample, 6 fieldswere estimated and
averaged (n ¼ 6 at each time point). The number of cells migrating into the
graft fabric was counted on HE-stained sections. The number of nuclei per
unit areawas estimated in 10 fields in each sample (n¼ 6 at each time point).Quantitative Real-Time Polymerase Chain Reaction
Total RNAwas extracted from the neointima using the RNeasy Kit and
reverse transcribed using Omniscript Reverse transcriptase (Qiagen,
Hilden, Germany). Real-time polymerase chain reaction was performed
with ABI PRISM 7700 (Applied Biosystems, Foster City, Calif) using
the primers for VEGF (cf02623449-m1), SDF-1 (cf02625258-m1), and
beta-2-microglobulin (cf2659077-m1) (Applied Biosystems). The average
copy number of gene transcripts for VEGF or SDF-1 was normalized to the
beta-2-microglobulin gene.
In Vitro Study
Aortic smooth muscle cells, aortic fibroblasts, or aortic endothelial cells
of human origin (Lonza, Basel, Switzerland) were cultured in serum-freegery c November 2014
FIGURE 1. A, ONO-1301 release curve of ONO-1301 microspheres synthesized with PLA polymers. The drug-eluting capacity was sustained even at
3 months after the initiation of degradation. B, The stent grafts were handmade and composed of stainless-steel Z stent and woven polyester graft.
C, The canine abdominal aorta was exposed via the retroperitoneal approach. D, The stent graft was introduced into the thoracic aorta under fluoroscopic
guidance, followed by post-balloon dilatation. E, Stent materials were removed from the extracted specimen and sectioned for assessments.




Smedium for 24 hours and then incubated with 0 nM, 10 nM, 100 nM, and
1000 nM of ONO-1301 (n ¼ 3 each). Supernatant was collected after 72
hours (24 hours in endothelial cells because of their tendency to degrade
in the serum-free medium), and VEGF and SDF-1 levels were measured
using an enzyme-linked immunosorbent assay kit (R&D Systems Inc,
Minneapolis, Minn).
Statistical Analysis
Continuous variables are summarized as mean  standard deviation.
Concentrations of ONO-1301 in the aortic wall were compared using
1-way analyses of variance, followed by post hoc pairwise independent t
tests. Exposed stent length and biomechanical and histologic assessment
data were analyzed using 2-way analyses of variance with each groupThe Journal of Thoracic and Carand month as the main effects and the first-order interaction effect between
each parameter, followed by post hoc pairwise independent t tests. In vitro
data were analyzed through pairwise comparisons between the control
(0 nM) and the other levels of ONO-1301 (10, 100, and 1000 nM). The
multiplicity in pairwise comparisons was corrected using the Bonferroni
method. All probability values are 2-sided. Statistical analysis was
performed with JMP software (SAS Institute Inc, Cary, NC).RESULTS
Procedure-Related Mortality and Morbidity
Thirty-six animals completed the study, and 2
animals failed to complete; 1 died of cardiac arrhythmiadiovascular Surgery c Volume 148, Number 5 2327
FIGURE 2. A, ONO-1301 concentration in the aortic wall in the ONO(þ) group. Although the drug concentration at the graft attachment site decreased
over time, it remained in the effective range over 3 months (*P<.05 vs 1 month). B, Plasma ONO-1301 levels in the ONO-1301(þ) group. The drug
concentration remained below the safety level. C, Macroscopic view of the inner lumen. Neointimal formation and thrombus degradation progressed,
and this process was observed earlier in the ONO(þ) group. D, The exposed stent length decreased over time and was shorter in the ONO(þ) group
(yP<.05 vs 1 month of the corresponding group). ANOVA, Analysis of variance.




Simmediately after sheath removal, and the other was
euthanized because of persistent paraplegia. Transient
hemiparaplegia was observed in 3 animals after the
procedure; however, they completely improved with sup-
plemented glucose solution infusion. Neither an embolic
event nor stent graft migration occurred in any animal.
Stable ONO-1301 Concentrations in the Aortic Wall
and Blood Plasma
Although the ONO-1301 concentrations in the aortic
wall tissue under the stent graft attachment site
decreased gradually until 3 months after the implantation,
they remained within the effective range at 3 months2328 The Journal of Thoracic and Cardiovascular Sur(Figure 2, A). The blood plasma ONO-1301 concentrations
were the highest at 5 minutes after the ONO-1301–eluting
stent graft implantation; they gradually decreased over
2 weeks, slightly increased at 1 month, and decreased at
3 months after the procedure (Figure 2, B). ONO-1301
was not detected in any samples, including aortic wall tissue
or blood plasma, from the ONO() group.
Enhanced Adventitial Neovascularization and
Neointimal Formation by ONO-1301 Elution
The adventitial appearance and neointimal formation in the
aorta were assessed after the stent graft implantation in the
ONO(þ) group and compared with that in the ONO()gery c November 2014
FIGURE 3. A, Tensilon RTC-1150A (Orientec, Tokyo, Japan). B, Tension was applied to the specimen placed into the metallic cylinder of the machine
using mosquito clamps. C, The maximal load required to displace the graft from the aortic wall was evaluated by the load-deformation plot. D, The
maximum load needed to displace the graft fabric from the aortic wall increased over time and was greater in the ONO-1301(þ) group than in the
ONO() group, especially 2 months after surgery (*P<.05 vs ONO() group, yP<.05 vs 1 month of the corresponding group, zP<.05 vs 2 months
of the corresponding group). ANOVA, Analysis of variance.




Sgroup. At 2 months after stent graft implantation, the adven-
titia of the aorta showed rich vasculature corresponding to the
stent graft implantation site compared with the area remote
from the stent graft in both groups; further, this vasculature
appeared to be increased in the ONO(þ) group compared
with that in the ONO() group (Figure E1, A and B). In the
inner lumen of the stent graft implantation site, progression
of neointimal formation and a decrease of red thrombus under
the neointima were observed in both groups in a time-
dependent manner; however, these changes occurred earlier
in the ONO(þ) group than in the ONO() group (Figure 2,
C). The length of the exposed stent in the inner lumen, which
indicates poor neointimal formation, significantly decreased
over time (P¼ .0011) and was greater in the ONO() group
than in the ONO(þ) group (P ¼ .0050) (201.1%  89.8%,
187.1%  127.6%, and 134.5%  109.8% at 1, 2, and 3
months, respectively) (Figure 2, D). Hemodynamic stenosis
of the inner lumen by excessive neointimal formation was
absent in all of the samples.
Enhanced Mechanical Force Required to Detach the
Graft From the Aorta by ONO-1301
The maximum detachment load gradually increased in
both groups over the 3 months (P < .0001). Moreover,
maximum load required at 2 months was substantiallyThe Journal of Thoracic and Cargreater than at 1 month in both groups and then did
not differ from that at 3 months in both groups (250.1%
 43.3% [2 months vs 1 month] and 110.2%  12.4%
[3 months vs 2 months] in the ONO(þ) group; 218.6% 
20.4% [2 months vs 1 month] and 123.1%  9.0%
[3 months vs 2 months] in the ONO() group), suggesting
that the tissue healing process was almost accomplished at
approximately 3 months. On the other hand, the maximum
load required in the ONO(þ) group was significantly
greater than that in the ONO() group (P ¼ .0007), espe-
cially at 2 months (P ¼ .0492) (117.1%  44.4%,
133.9%  23.2%, and 119.9%  13.5% at 1, 2, and 3
months, respectively) (Figure 3).Histologic Evidence of Enhanced Neointimal
Formation by ONO-1301 Elution
In HE-stained sections, the inner graft surfacewas covered
by denser neointima to produce a smooth surface in the
ONO(þ) group than in the ONO() group at 2 months
(Figure 4, A-C). In addition, the neointima contained richer
CD31-positive capillary networks in the ONO(þ) group
than in the ONO() group at 2 months (Figure E1, B and
C). Moreover, the neointima contained rich aSMA-positive
cell components with fibrous components in the ONO(þ)diovascular Surgery c Volume 148, Number 5 2329
FIGURE 4. A-C, Neointimal tissue was observed on the graft fabric; new tissue also was seen between the aortic wall and the graft fabric (HE staining:
A, ONO(þ); B, ONO() at 2 months; C, The scheme). D, Fibrotic area was assessed using Masson’s trichrome staining. The% fibrotic area increased in a
time-dependent manner and was greater in the ONO treatment group, especially at 2 and 3 months (% fibrotic area [%]¼ [fibrotic area]/[total tissue area]).
Scale bar¼ 200 mm. E, Migrating cells into the graft fabric were assessed by HE staining. The cell density was greater in the ONO(þ) group at both 1 and 2
months after the procedure (cell density ¼ [cell counts]/[area of graft fabric]). Scale bar ¼ 50 mm (*P<.05 vs ONO() group, yP<.05 vs 1 month of the
corresponding group, zP<.05 vs 2 months of the corresponding group). ANOVA, Analysis of variance.
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FIGURE 5. A, Messenger RNA expressions of VEGF and SDF-1 were analyzed in the neointimal tissue (ie, area stained red). The expressions of VEGF
and SDF-1 tended to be upregulated at 1 month and 3 months. B, Immunohistochemically, the IP receptor in the aortic wall was coexpressed with CD31-
positive, aSMA-positive, and fibroblast-specific antigen-1–positive cells. Scale bar ¼ 50 mm. C, The expressions of VEGF and SDF-1 were upregulated
when ONO-1301 was added to the culture medium of aortic smooth muscle cells and aortic fibroblasts (*P<.05 vs 0 nM). FSP, Fibroblast specific antigen;
SDF, stromal cell-derived factor; SMA, smooth muscle actin; VEGF, vascular endothelial growth factor; IP, prostacyclin; CD, cluster of differentiation.
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Sgroup compared with the ONO() group, wherein sparse
fibrous components predominated with a small number of
aSMA-positive cells (Figure E1, D and E).
Histologic Evidence of Enhanced Tissue
Accumulation Under the Graft by ONO-1301
Fibrous tissue components gradually predominated in the
gap between the graft and the aortic wall with decreased red
thrombus in a time-dependent manner in both groups
(P<.0001). These fibrotic areas were significantly larger in
the ONO(þ) group than in the ONO() group (P<.0001),
especially at 2 and 3 months after stent graft implantation
(P ¼ .0110 and P ¼ .0129, respectively) (117.1% 
13.9%, 117.2%  7.1%, and 122.8%  6.2% at 1, 2, and
3 months, respectively) (Figure 4, D). Moreover, the number
of cells present inside the graft fabric significantly increased
over time (P ¼ .0005), and a greater number of cells were
present in the ONO(þ) group than in the ONO() group
(P ¼ .0003), especially at 1 and 2 months after graft
implantation (P ¼ .0162 and P ¼ .0111, respectively)
(135.9%  17.0%, 134.9%  22.3%, and 111.6% 
26.2% at 1, 2, and 3 months, respectively) (Figure 4, E).
Potential Association of Vascular Endothelial
Growth Factor and Stromal Cell-Derived Factor 1
With the Positive Effects of ONO-1301 Elution
The expressions of VEGF and SDF-1 in the neointimal tis-
sue were analyzed to explore potentially associated factors
with the histologic changes. The expressions of both VEGF
and SDF-1 tended to be upregulated in the ONO(þ) group
compared with the ONO() group at 1 month and 3 months
(not statistically significant) (Figure 5, A). In addition, the
aortic wall of the stent graft implantation site at 2 months
contained a number of CD31-positive endothelial cells,
aSMA-positive smooth muscle cells, or myofibroblasts, and
fibroblast specific antigen-1–positive fibroblasts that were
also positive for prostacyclin (IP) receptor, to which
ONO-1301 acts as a ligand (Figure 5, B). The ONO-1301
concentration-dependent VEGF and SDF-1 expression in
the aortic endothelial cells, aortic smooth muscle cells, and
aortic fibroblasts of human origin invitrowere assessed using
enzyme-linked immunosorbent assay (Figure 5, C). VEGF
and SDF-1 secretion from the aortic smooth muscle cells
and fibroblasts increased significantly,with a positive correla-
tion with ONO-1301 concentrations. In contrast, no increase
in VEGF and SDF-1 secretion from the aortic endothelial
cells was evident after the addition of ONO-1301.
DISCUSSION
This study demonstrated that the creation of an ONO-
1301–eluting stent graft and the fluoroscopy-guided
implantation of this graft into the thoracic aorta of
normal canines were feasible and safe, producing high
ONO-1301 concentrations in the aortic tissue underlying2332 The Journal of Thoracic and Cardiovascular Surthe graft-implanted site for up to 3 months; further, the
systemic blood plasma concentrations remained well below
the safety levels.9 Implantation of the ONO-1301–eluting
stent graft resulted in stronger, denser, and more fibrous
adhesion between the aortic wall and the graft in addition
to increased expression of factors associated with adhesion,
blood vessel creation, and tissue healing, when compared
with the stents without ONO-1301.
To the best of our knowledge, this is the first report of the
effects of ONO-1301 elution on stent graft attachment to the
aortic wall, although several attempts to enhance the
biological prosthetic graft attachment to the aortic wall
have been reported. Lerouge and colleagues15 reported
the results of an in vitro study in which nitrogen-rich
polymerized plasma promoted the cell ingrowth in poly-
ester and polytetrafluoroethylene graft fabric. Charbonneau
and colleagues16 reported an in vitro study wherein
incorporation of chondroitin sulfate in the stent graft
enhanced cell adhesion and viability. However, the in vivo
feasibility or safety of these technologies remains unclear,
whereas this study demonstrated the feasibility and safety
of an ONO-1301–eluting stent graft using a clinically
relevant implantation method in a large animal model.
Although van der Bas and colleagues17 reported that
coating stent grafts with basic fibroblast growth factor–
impregnated collagen enhanced ingrowth into the fabric
and neointimal formation in the aorta in a swine model, it
may be reasonable to suggest that the ONO-1301–eluting
stent graft is more advantageous in the clinical setting
because it releases the drug over 3months postimplantation,
potentially contributing to an enhanced healing process
between the stent graft and the aortic wall that would
progress past the 3 months, as reported previously18 and
confirmed in this study. However, the ONO-1301 dose, graft
material, and creation protocol for the stent graft need to be
optimized for clinical studies.
ONO-1301 produces various tissue healing effects on
damaged tissues or organs where it is administered by
acting on endothelial cells, vascular smooth muscle cells,
and fibroblasts via binding with the IP receptor.11 In fact,
the aorta contains cells that express the IP receptor and
various factors associated with tissue healing, such as
VEGF and SDF-1. VEGF has been reported to promote
endothelial cell migration and angiogenesis,19,20 whereas
SDF-1 induces the local homing of bone marrow cells
through the SDF-1/CXCR4 axis, which promotes
neointimal formation and neovasculogenesis.21,22 These
factors were upregulated depending on ONO-1301
concentrations, indicating that the biological effects of
ONO-1301 led to enhanced neointimal formation and
fibrous tissue, filling the gap and strengthening the
mechanical force of the attachment between the graft and
the aortic wall. Moreover, through the prostaglandin I-IP
system, endothelial progenitor cells have been reported togery c November 2014




Srecruit to the injured vessels and participate in reendo-
thelialization.23 One may assume that ONO-1301 would
produce negative effects on tissue fibrosis via the
upregulation of antifibrotic factors, such as hepatocyte
growth factor, although this was not observed in the present
study. However, antifibrotic effects by ONO-1301 have
been reported in pathologies wherein the accumulation of
fibrotic components exacerbates tissue or organ damage,
such as that occurring in advanced cardiac failure and
pulmonary fibrosis.7,8 It is possible that ONO-1301 acts in
a regenerative manner, with effects that are antifibrotic or
profibrotic depending on the existing pathology.
In this study, the ONO-1301–eluting stent was examined
to extend the indication of endovascular treatment for
complicated aortic morphologies or anatomies, such as
short neck, severely angulated neck, or reverse taper, for
which treatment using presently available stent grafts is
not indicated. Adhesive properties of the stent graft are of
great benefit in these cases in which only a short landing
zone is available. As shown in this study, the ONO-1301–
eluting stent graft has greater adhesive properties than the
standard stent graft, indicating the usefulness of this new
stent graft for these pathologies. Considering that endoleaks
are primarily due to arch curvature or folds that prevent
contact between the graft and aortic wall, which was also
observed in the present study, the adhesive properties of
the method we present may be of limited benefits. However,
our data showed that the space between the graft and the
aortic wall could be filled with newly generated tissue,
suggesting that the new device might prevent the
fold-related type I endoleak.
Study Limitations
This study is limited by the use of a normal animal
model rather than a pathologic model. The biological
response toward ONO-1301–eluting stents in human
atherosclerotic aortic aneurysms would differ from that
observed in the current study. However, the human aortic
aneurysm border zone, where the stent graft is deployed,
is known to contain a greater number of activated inflamma-
tory cells than the normal aortic wall.24,25 These cells may
synergistically activate the adjacent cells in the aortic wall
after ONO-1301 administration, contributing to enhanced
biological stent graft attachment to the aorta.26 Further
basic and preclinical studies are needed to clarify these
issues.
In regard to the safety of prostacyclin against the
atherosclerotic aortic aneurysm wall, prostacyclin is
reportedly produced from the endothelial cells through the
cyclooxygenase (COX)-1 axis in the presence of a stable
condition and has a protective effect on the aortic wall. In
the presence of vascular damage, COX-2 is induced
and produces prostacyclin for vascular protection.
However, with significant inflammation or disease,The Journal of Thoracic and Carincreased COX-2 expression produces a large amount of
alternative prostanoids (eg, prostaglandin E2) that induce
matrix metalloproteinases and cell death, resulting in tissue
destruction and vascular lesion instability.27,28 King and
colleagues29 reported that these destructive effects are
similar to those that occur in abdominal aortic aneurysms.
On the other hand, hepatocyte growth factor, which is
reportedly induced from ONO-1301–exposed fibroblasts
or smooth muscle cells,9,11 could have anti-inflammatory
effects in human abdominal aortic aneurysms.30 Therefore,
prostacyclin has a theoretically protective effect on the
aortic wall and should not be associated with aneurysm
progression, and in the present study, atherosclerotic
changes were not observed in this canine model. Moreover,
no adverse effect was observed on aneurysmal formation or
progression with the clinical use of iloprost (a synthetic
prostacyclin analog) in the treatment of pulmonary
hypertension.31,32 These findings support the safety of
prostacyclin in the aortic aneurysm pathology; however,
its safety should be verified using an atherosclerotic
aneurysm animal model, which may prove difficult
because of the lack of an available atherosclerotic large
animal model.CONCLUSIONS
ONO-1301 elution over the stent graft strengthened the
mechanical and biological attachment of the stent graft to
the native aortic wall via enhanced neointimal formation
over the graft surface and enhanced migration of fibrous
tissue components into the graft in a normal canine
model. This new device may be useful in preventing stent
graft–related complications associated with inadequate
attachment between the graft and the aortic wall, although
further studies are warranted.
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FIGUREE1. A and B, Adventitia of the aorta at 2 months in the ONO(þ) group (A) and ONO() group. B, Solid line: stent graft implantation area, dotted
line: nonimplantation area. C-F, CD31-positive capillary networks increased, and aSMA-positive components were denser in the neointimal tissues in the
ONO(þ) group than in the ONO() group (C and E, ONO(þ); D and F: ONO() at 2 months). Scale bar¼ 500 mm. SMA, Smooth muscle actin;CD, cluster
of differentiation.
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